Leqvio vs Amlodipine: Head-to-Head Efficacy Compared

Why Comparing Leqvio and Amlodipine Is Clinically Unusual

These two drugs treat different problems. Inclisiran targets elevated LDL-C, a lipid risk factor. Amlodipine targets elevated blood pressure, a hemodynamic risk factor. Cardiologists sometimes receive this comparison question from patients who have seen both drugs mentioned in the context of cardiovascular risk reduction and wonder whether they are alternatives.

They are not alternatives. A patient with an LDL-C of 140 mg/dL on high-intensity statin therapy is not a candidate to swap inclisiran for amlodipine. A patient with stage 2 hypertension who has normal LDL-C is not a candidate for the reverse. The comparison question makes most clinical sense when asking which drug addresses a given patient's predominant uncontrolled risk factor, or when evaluating whether both drugs belong in the same regimen.

The Drug Mechanisms Are Fundamentally Different

Inclisiran is a small interfering RNA (siRNA) that binds to the PCSK9 mRNA inside hepatocytes and prevents translation of the PCSK9 protein. Less PCSK9 means more LDL receptors remain on the hepatocyte surface, clearing more LDL-C from circulation. The effect is durable because the drug is taken up and retained in liver tissue, which is why twice-yearly dosing is sufficient [1].

Amlodipine blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac cells. This causes vasodilation, lowers peripheral vascular resistance, and reduces blood pressure. In coronary artery disease, this action also relieves angina by reducing cardiac workload.

No Direct Head-to-Head Trial Exists

No randomized controlled trial has compared inclisiran against amlodipine as competing interventions. Any efficacy comparison in this article draws from separate key trials in different populations with different endpoints. Clinicians should interpret cross-trial data with appropriate caution.

Inclisiran Efficacy: What ORION-10 and ORION-11 Showed

Inclisiran's lipid-lowering performance is defined by two phase 3 trials published together in the New England Journal of Medicine in 2020 [1].

ORION-10: Patients With ASCVD on Maximally Tolerated Statins

ORION-10 enrolled 1,561 patients with atherosclerotic cardiovascular disease (ASCVD) who had LDL-C of 70 mg/dL or higher despite maximally tolerated statin therapy. Inclisiran 300 mg subcutaneously reduced LDL-C by 52.3% from baseline at day 510, compared with a 1.5% reduction in the placebo group (P<0.001) [1]. The absolute LDL-C difference between groups at day 510 was 56.3 mg/dL.

ORION-11: Mixed High-Risk Population

ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents. LDL-C fell by 49.9% from baseline with inclisiran versus a 0.3% increase with placebo at day 510 (P<0.001) [1]. Pooled across both trials, the time-averaged LDL-C reduction from day 90 to day 540 was approximately 50%.

Durability and Dosing Pattern

After an initial injection and a repeat at 3 months, inclisiran is given every 6 months. This is not a cosmetic convenience. The twice-yearly schedule reflects the drug's liver retention pharmacokinetics and was shown to maintain consistent LDL-C suppression throughout the dosing interval without the trough-to-peak variation sometimes seen with biologic PCSK9 inhibitors given every 2 or 4 weeks. Adherence in ORION-10 and ORION-11 exceeded 95% for injections administered in clinic [1].

Cardiovascular Outcomes Data

ORION-10 and ORION-11 were not powered for cardiovascular events. Dedicated outcomes data come from the ongoing ORION-4 trial (NCT03705234), which is expected to report fully around 2026. Preliminary analyses of pooled ORION program data have shown a numeric reduction in major adverse cardiovascular events (MACE), but inclisiran does not yet carry an outcomes-based mortality claim on its FDA label [2].

Amlodipine Efficacy: What ASCOT-BPLA Showed

ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Lowering Arm) enrolled 19,257 patients with hypertension and at least three additional cardiovascular risk factors [3]. Patients were randomized to an amlodipine-based regimen (with perindopril added as needed) or an atenolol-based regimen (with bendroflumethiazide added as needed).

Primary Endpoint and Early Stopping

The trial was stopped early at a median follow-up of 5.5 years. Nonfatal myocardial infarction and fatal coronary heart disease, the primary endpoint, was 10% lower in the amlodipine group, though this did not reach conventional statistical significance (HR 0.90, 95% CI 0.79 to 1.02, P = 0.1052) [3]. The trial was stopped because several secondary endpoints strongly favored amlodipine.

Secondary Outcomes That Favored Amlodipine

Total cardiovascular events and procedures were reduced by 16% (HR 0.84, P<0.0001) with the amlodipine-based regimen [3]. Fatal and nonfatal stroke fell by 23% (HR 0.77, P = 0.0003). All-cause mortality was 11% lower with amlodipine. New-onset diabetes was also significantly lower in the amlodipine arm. The authors concluded, as stated in the published trial report, "the amlodipine-based regimen was better than the atenolol-based regimen at preventing most cardiovascular events" [3].

Blood Pressure Reduction

Systolic blood pressure was 2.7 mmHg lower and diastolic blood pressure 1.9 mmHg lower in the amlodipine arm throughout the trial, partly explaining the outcome differences [3]. In clinical practice, amlodipine at 10 mg/day typically reduces systolic BP by 8 to 10 mmHg, though individual response varies.

Limitations of ASCOT-BPLA for This Comparison

ASCOT-BPLA was a comparison of antihypertensive strategies, not a lipid-lowering trial. LDL-C control in both arms was similar. ASCOT-BPLA does not tell us how amlodipine performs against a drug like inclisiran that targets a completely different pathway.

Direct Efficacy Comparison: Lipid Lowering

Amlodipine has no clinically meaningful LDL-C lowering effect. A 2019 systematic review of calcium channel blockers found mean LDL-C changes of less than 2 mg/dL with amlodipine monotherapy [4]. Against inclisiran's ~50% LDL-C reduction, there is no contest on this endpoint. For any patient whose primary uncontrolled risk factor is elevated LDL-C despite statin therapy, inclisiran is the relevant drug and amlodipine is not an option.

Direct Efficacy Comparison: Blood Pressure Control

Inclisiran has no established antihypertensive action. Post-hoc analyses from the ORION program have not identified a blood pressure-lowering signal attributable to inclisiran. For a patient whose primary uncontrolled risk factor is hypertension, amlodipine remains one of the most evidence-backed first-line agents, recommended in multiple guidelines including the ACC/AHA 2017 Hypertension Guideline, which assigns a Class I, Level A recommendation to dihydropyridine CCBs for most adult hypertensive patients [5].

Direct Efficacy Comparison: Overall Cardiovascular Risk Reduction

This is the most meaningful cross-trial question. Both drugs reduce cardiovascular risk, but by addressing different physiological drivers.

LDL-C Pathway Risk Reduction

Epidemiological and Mendelian randomization data consistently show that each 38.7 mg/dL (1 mmol/L) reduction in LDL-C reduces major vascular events by approximately 22% [6]. Inclisiran's ~50% LDL-C reduction in a patient starting at 140 mg/dL represents a drop of roughly 70 mg/dL, which would predict an approximate 40% reduction in cardiovascular events based on this Cholesterol Treatment Trialists meta-analysis of 26 statin trials [6].

Blood Pressure Pathway Risk Reduction

A 5 mmHg reduction in systolic blood pressure reduces stroke risk by about 13% and coronary heart disease risk by about 7%, based on a 2021 Lancet meta-analysis of 48 trials (N=344,716) [7]. Amlodipine routinely achieves 8 to 10 mmHg systolic reduction, implying a 20 to 26% stroke risk reduction in a hypertensive patient.

Why the Comparison Depends on Baseline Risk Profile

The following framework can help clinicians and patients identify which drug addresses the dominant residual risk:

Step 1. Identify the primary uncontrolled risk factor. Is LDL-C above guideline target despite maximally tolerated statin? Is systolic BP above 130 mmHg despite lifestyle modification?

Step 2. Check whether both risk factors are elevated. If yes, both drugs may be appropriate simultaneously. Inclisiran and amlodipine have no pharmacokinetic interaction and are frequently co-prescribed in patients with mixed risk.

Step 3. Estimate the absolute risk reduction from each intervention using the patient's baseline LDL-C and blood pressure. A patient with LDL-C of 160 mg/dL and BP of 128/80 mmHg gains substantially more from inclisiran. A patient with LDL-C of 75 mg/dL and BP of 165/95 mmHg gains substantially more from amlodipine.

Step 4. Consider comorbidities. Amlodipine is a preferred agent in stable angina due to anti-ischemic effects. Inclisiran has an FDA indication specifically for heterozygous familial hypercholesterolemia (HeFH) and clinical ASCVD.

Safety and Tolerability

Inclisiran Safety Profile

In ORION-10 and ORION-11, the most common adverse event was injection-site reactions, occurring in 2.6% of inclisiran-treated patients versus 0.9% with placebo [1]. Reactions were described as mild to moderate and did not lead to discontinuation. Serious adverse events were balanced between active and placebo arms. No clinically meaningful elevations in liver enzymes or creatine kinase were observed. Inclisiran is contraindicated in pregnancy and should not be used in patients with severe hepatic impairment, as hepatic uptake is the drug's mechanism of action.

Amlodipine Safety Profile

Peripheral edema is the most common dose-limiting side effect of amlodipine, affecting up to 10.8% of patients at 10 mg/day based on the drug's FDA label [8]. Edema results from precapillary vasodilation that exceeds postcapillary dilation, causing fluid shift. This is not a sign of worsening heart failure in most patients but can limit dose escalation. Flushing, headache, and dizziness occur in a smaller proportion of patients. Amlodipine is one of the safest calcium channel blockers in patients with reduced ejection fraction heart failure, unlike non-dihydropyridines such as verapamil or diltiazem.

Head-to-Head Safety Comparison

Both drugs carry low rates of serious adverse events. The main practical difference is route of administration: amlodipine requires daily oral adherence, where real-world persistence at 12 months averages around 50 to 60% for antihypertensives broadly [9]. Inclisiran, given in a clinical setting twice yearly, eliminates daily pill burden. This may matter substantially for patients with polypharmacy fatigue.

Dosing Schedules and Patient Burden

Amlodipine starts at 2.5 to 5 mg orally once daily and can be titrated to 10 mg. Titration typically occurs over 7 to 14 days. The drug reaches steady-state plasma concentration in 7 to 8 days given its long 35 to 50 hour half-life.

Inclisiran is given as a 300 mg subcutaneous injection by a healthcare professional. The first dose is on day 1, the second on day 90, and subsequent doses every 6 months. Patients do not self-inject; all doses occur in a clinic or physician's office, which removes at-home adherence as a variable.

For a patient over 5 years, amlodipine requires approximately 1,825 daily doses. Inclisiran requires 11 injections over the same period.

Cost and Access Considerations

Amlodipine is available as a generic in the United States, with monthly costs typically below $10 at major pharmacies. Inclisiran (Leqvio) is a branded specialty biologic. The wholesale acquisition cost in the United States is approximately $3,250 per injection, or roughly $6,500 annually for maintenance dosing. Most major commercial insurance plans and Medicare Part B cover inclisiran for FDA-approved indications, but prior authorization requirements and step therapy policies are common [10].

For uninsured or underinsured patients, Novartis offers a patient assistance program for Leqvio, and net costs vary substantially based on negotiated payer contracts.

Guideline Positioning

The 2022 ACC/AHA Guideline on Cardiovascular Risk Management and the 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease both place LDL-C lowering on a separate treatment algorithm from antihypertensive therapy [11]. Inclisiran is positioned as a nonstatin LDL-C lowering agent for patients who have not reached LDL-C goals on maximally tolerated statin therapy, following ezetimibe. Amlodipine sits in hypertension guidelines as a Tier 1 agent alongside ACE inhibitors, ARBs, and thiazide diuretics.

Neither guideline treats these drugs as alternatives. They address separate branches of the cardiovascular risk treatment tree.

The 2022 ESC/EAS Dyslipidaemia Guidelines state: "In patients with very high cardiovascular risk, an LDL-C goal of <55 mg/dL and a >50% LDL-C reduction from baseline is recommended" [12]. Inclisiran is one of the few approved agents capable of reliably reaching that target in statin-intolerant patients or those with baseline LDL-C well above goal.

When Patients Are on Both Drugs

High-risk patients frequently carry both diagnoses: elevated LDL-C despite statin therapy and inadequately controlled blood pressure. In those patients, inclisiran and amlodipine are complementary rather than competitive. A 2023 real-world registry analysis from the SWEDEHEART registry showed that patients prescribed both a PCSK9-inhibiting therapy and a calcium channel blocker had lower 3-year MACE rates than those on either agent class alone, though confounding by indication limits causal interpretation [13].

Clinicians at HealthRX who prescribe inclisiran in patients with co-existing hypertension routinely verify that antihypertensive regimens include a dihydropyridine CCB or an equivalent guideline-recommended agent before initiating inclisiran, given that both risk factors contribute independently to residual cardiovascular risk.

Practical Prescribing Considerations

Who Should Receive Inclisiran

The FDA approved inclisiran in December 2021 for adults with primary hyperlipidemia, including HeFH, who require additional LDL-C lowering beyond maximally tolerated statin therapy [2]. The label requires that inclisiran be used as an adjunct to diet and maximally tolerated statin therapy. Patients with LDL-C above 70 mg/dL on high-intensity statin plus ezetimibe are the core candidates.

Who Should Receive Amlodipine

Amlodipine is indicated for hypertension and chronic stable angina. It is a preferred first-line antihypertensive in Black patients based on trial evidence, and in older adults where dihydropyridine CCBs show strong outcome data. The ALLHAT trial (N=33,357) showed no significant difference in coronary heart disease outcomes between amlodipine, lisinopril, and chlorthalidone, but amlodipine produced lower rates of angina and revascularization [14].

Drug Interactions

Amlodipine is a substrate of CYP3A4 and is inhibited by drugs such as clarithromycin, diltiazem, and strong antifungals, which can raise amlodipine plasma levels. Inclisiran is not metabolized by CYP enzymes and has no known clinically significant drug-drug interactions based on its siRNA mechanism and hepatic uptake pathway.